safety & efficacy of devices for human use until 2001, when FDA has approved this method of treatment. 6 The area of pediatric cardiac interventional treatment has been extended from closure ASD/VSD/PDA & valvuloplasty to closure of Rupture sinus of valsalva, 7 Aorto-Pulmonary (AP) window, 8 Coronary Cammeral fistula, 9 PDA stenting in Pulmonar atresia, 10 Percutaneous Pulmonary Valve Replacement (PPVR), 11 & Percutaneous Aortic Valve Replacement (PAVR). 12 Further it has been extended up to Hybrid procedures along with surgeon for the treatment large VSD/ ASD closure in very young Infant, Palliation in Hypoplastic Left heart syndrome with PDA stenting & surgical bilateral pulmonary artery banding, 13 & Fontan Completion. 14 As the interventional procedure is costly compared to surgical one, so the number of intervention is less in our center with respect to total patient load. We are presenting our initial experiences & outcome of pediatric cardiac interventions at NICVD.
Methods & Materials:
Patients with congenital heart diseases both inpatient and outpatient department of NICVD were scrutinized with Echocardiography to find out the suitable candidate for Interventional treatment. In January 2005, we first performed the device closure method with PDA. Since For selection of size of PDA device, we added 2-3 mm more to the diameter of the pulmonary end of the PDA. Among PM VSD cases, one was 3x4 mm size with 3mm distance from Aortic valve & other was 5x6 mm in size having 4-5 mm distance from aortic valve. In first case we failed to cross the VSD but in second case it was , successful with 6/6 mm (Diameter/Length) Amplatzer Duct Occluder 11 (ADO II).
For pulmonary Balloon Valvuloplasty, size of the balloon was selected on the basis of Echo/ Angiographic measurement of the pulmonary valve annulus. In most of the cases of infant & pediatric patient we multiply with 1.25 times more than that of the pulmonary annulus. But in older patients than 10 years we selected multiplying 1.5 times than that of pulmonary annulus. For Aortic Balloon Valvuloplasty, the size of the balloon was determined on the basis of 0.8-0.9% of the aortic annulus or the size of the abdominal aorta at the level of Diaphragm measured by Echo/ Angiography. All but 6 of the Aortic balloon valvuloplasty were done with temporary overdrive pacing through right heart catheterization. For the Balloon Coarctoplasty, we measured the size of transverse arch/ size of the abdominal aorta at the level of Diaphragm to determine the size of the balloon. For PTMC, cases were selected on the basis of Echo findings, valve morphology of severity, pliability, absence of calcification & severity of mitral regurgitation. The size of the Innoe balloon was selected on basis of the height of the patients in centimeter divided by ten & then adding ten in mm. All the Balloon Atrial Septostomy patients were having d-TGA, IVS except one who has TAPVC with PFO. Most of our patients required general anesthesia except a few patients. In pulmonary balloon valvuloplasty (Table-IV In Aortic Balloon Valvuloplasty (Table-V) involving 20 cases, the mean pre-balloon AV annular size was 11 ± 3.0 mm. Mean balloon diameter was 12 ± 4.0 mm. Mean pre balloon gradient was 60 ± 25 mmHg. Mean post balloon gradient was 30 ± 15 mmHg. Only 2 (10%) patients developed trivial AR. All patients except 6 cases, the procedure were assisted with rapid RV pacing up to 180-210 with fall of BP around 50-60% of the baseline blood pressure for the maintenance of balloon stability across aortic valve. There was no complication associated with this overdrive rapid right ventricular (RV) pacing.
Results
In Coarctation Balloon Angioplasty ( In Balloon Atrial Septostomy (BAS), (Table-VIII) , out of 15 patients, the procedure in one patient failed & in other one the procedure was abandoned due to anesthetic overdoses followed by cardiac arrest in cathlab but recovered after resuscitation. In 13 patients, the procedures were successful increasing Oxygen saturation mean of 60% ± 15% to 78% ± 10% with p value of <0.05. 18 of PDA coil occlusion, 59% had immediate occlusion which increased up to 95% by one year follow-up. 10% had suboptimal outcome described as failure to implant, embolization, residual shunt or intravascular haemolysis/ haemoglobinuria. In our series of 20 patients of coil closuress, 85 % had complete closure after 6 months follow-up with Echo. One randomized trial compared percutaneous closure of PDA to surgery. In this study from China, Chen et al 19 compared 72 patients with device closure with 183 patients treated with surgery. More procedure related events were found in surgical group than device group (13.7% vs 1.4%), average recovery time was more prolonged in surgery group than device group (8.7 days vs 1.3 days). Freedom from residual shunt was higher in percutaneous group than surgery (98.6% vs 91.3%). 22, 23 In our series, out of 60 patients attempted for ASD device closure, 56 were successful, in 2 patients abandoned the procedure due to unsuitable rims, in one patient, a 24 mm Amplatzer device embolized to RV, another 16 mm device embolized to PA, which were subsequently surgically removed with patch closure of ASDs. We had no mortality. On short term & intermediate follow up for 36 months one patient had trivial MR, two patients had nonspecific chest pain which subsequently improved.
Device closure of VSD started by Lock et al first in 1987. 24 There are two types of Amplatzer VSD devices, one for muscular device & one for PM VSD device having unequal LV/RV disc to avoid injury to Aortic Valve. In both conventional methods arterio-venous loop is produced & ante grade approach via venous side is used for deployment of the device. In this method of PM VSD closure, incidence of complete heart block (CHB) is nearly 5%. 25 But recently non conventional use of ADO II in retrograde way for closure of PM VSD showed more promising result with no or very infrequent incidence of CHB. 26 We performed one case of PM VSD closure with ADO II with excellent outcome.
Pulmonary Balloon Valvuloplasty (BPV) provides long term relief of pulmonary valvular obstruction in the majority of patients. Brian W. McCrndle et al analyzed the long term outcome in 46 patients of BPV for congenital pulmonary valvular steosis & found significant long-term reduction in trans-valvular gradient from 70±36 mmHg to 23±16 mmHg within 2 years & 20±13 mmHg after 2 years. 27 In our series of 90 patients of BPV, we followed with Echo-colorDoppler up to 12 months and found significant reduction of transvalvular gradient from 67±25 to 26±15 mmHg (p<0.001) with symptomatic improvement.
First Balloon Aortic Valvuloplasty (BAV) for congenital Valvular AS was successfully performed by Lababidi in 1983. 28 Akbari Ashbag P, Shahmohammadi A in a comparative study of 115 patients between balloon valvuloplasty (48 cases) versus surgical (67 cases) aortic valvotomy showed the mean reduction in transvalvular gradient was greater in balloon group than surgical group (73.54 vs 45.03). Also there were less incidence of Aortic insufficiency; less morbidity & mortality in balloon intervention. 29 In our study we also found significant reduction in transvalvular gradient from 65±25 to 30±15 mmHg with symptomatic improvement. Rapid ventricular pacing to achieve balloon stability is also a safe & effective option & may reduce the degree of aortic incompetence by minimizing valve damage. 30 We also used this technique with good results.
Balloon Angioplasty in Coarctation of Aorta is an alternative to surgical repair in children. In a study of 8 neonates by Liang CD, Su WJ, Chang HT et al showed the significant reduction in transvalvular gradient from 36.4±12.0 to 7.5 ± 6.0 mmHg (p<0.001). 31 In another study involving 26 patients by Hijazi, Z M, Fahey J T, Kleienman C S et al found Balloon Angipoplasty useful in recoarctation. 32 Our results involving 22 patients is comparable to these results with reduction of pre-balloon to post balloon transcoarctation gradient from 70±25 to 25±15 mmHg (p<0.05) along with clinical improvement.
We also performed a few cases of multiple interventions in a single patient in a single setting without any morbidity & mortality.
Mitral stenosis is the commonest Rheumatic Valvular heart disease in developing countries including Bangladesh. 33 Until the early 1980s, surgery was the only possible treatment for severe valvular lesions; then a new alternative appeared as percutaneous balloon Valvuloplasty. 34 In moderate to severe form of MS, Percutaneous Transvenous Mitral commussurotomy (PTMC) may be the best way of palliation with good outcome and immediate relieve of symptoms. K. Inoue and colleagues were first to perform percutaneous mitral commussurotomy (PTMC) IN 1982. 35 In our series of 35 patients, we performed PTMC with Inoue balloon technique. There were significant increase in valvular area & decrease in transmitral valvular gradient with a p value <0.001. This result is comparable with the study of Kang & Park et al. 36 We had one incidence of hardwire related complication which is rare in literature except in one article described by Gourge T, Subban V, Soliranjan R et al, who faced the similar problem of non deflation of proximal balloon. 37 This kind of hardwire related complication is more common in multiple used/ reused balloon. Korkmaz S, Sazmaz H, Aksu T et al in a large series of 577 cases of PTMC, found statistically significant increase in MVA than pre-procedural MVA with hemodynamic improvement in univariate & multivariate analysis (p<0.001,HR:3.5). 38 Atrial septostomy is an emergency life saving procedure in many congenital heart diseases including d-TGA as a bridge to definitive procedure of Arterial Switch Operation (ASO). In a study of 192 patients of Balloon atrial septostomy (BAS) by Matter M et al shown that oxygen saturation increased from 65% ± 9% to 88% ± 3% 39 . In our series of BAS there was significant increase in oxygen saturation from 65% ± 15% to 78% ± 10%.
Conclusion:
It was evident from our studies that there is significant advancement in the field of pediatric cardiac interventional treatment. There is least morbidity & mortality in all kinds of pediatric cardiac interventional procedures. So in future more & more challenging interventional treatment, in structural & congenital heart disease can be performed successfully.
